What is IGC Pharma?
Founded in 2005 and headquartered in Potomac, Maryland, IGC Pharma is dedicated to enhancing women's health and well-being through the discovery and commercialization of novel therapeutic agents. The company's research and development efforts are focused on addressing unmet medical needs in areas such as Alzheimer's disease, premenstrual syndrome (PMS), dysmenorrhea, and sleep disorders. IGC Pharma aims to bring these innovative treatments to market, offering new solutions for patients and their families.
How much funding has IGC Pharma raised?
IGC Pharma has raised a total of $3M across 1 funding round:
Share Placement
$3M
Share Placement (2023): $3M with participation from The Bradbury Group
Key Investors in IGC Pharma
The Bradbury Group
The Bradbury Group, established in 1959, is a manufacturing entity based in Kansas, specializing in metal products. Their involvement suggests a strategic interest in companies with tangible operational or developmental potential, possibly aligning with IGC Pharma's long-term growth trajectory.
What's next for IGC Pharma?
With this substantial backing, IGC Pharma is poised for accelerated growth and the advancement of its therapeutic candidates through critical clinical development stages. The strategic investment is expected to fuel further research, expand its operational capacity, and potentially facilitate key partnerships. This infusion of capital signals a pivotal moment for the company as it moves towards bringing its promising therapies to patients, reinforcing its position in the competitive pharmaceutical landscape.
See full IGC Pharma company page
